Srinagar June 06 (KNS): In a remarkable academic milestone for Indian dermatology, Dr. Mir Shahnawaz, a leading dermatologist and Founder & Director of DERMIS Skin & Hair Clinic, Bemina, has earned international acclaim with the publication of his groundbreaking research in the CUREUS Journal, a globally recognized, PubMed-indexed platform under Springer.

Titled “Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis,” the study represents the first comparative real-world clinical research from India to evaluate these three systemic therapies, including Abrocitinib, a novel selective JAK-1 inhibitor.Click Here To Follow Our WhatsApp Channel

Dr. Shahnawaz is among the very few dermatologists in India to have not only used Abrocitinib in clinical practice but also actively advocated its role as an effective and well-tolerated treatment option for patients suffering from moderate to severe Atopic Dermatitis. His findings provide crucial data for the Indian subcontinent and contribute to the evolving global dialogue on immunomodulatory therapy in dermatology.

The publication of this study places Dr. Mir Shahnawaz among the emerging academic voices in Indian dermatology and marks a significant step in bridging the gap between global innovations and local clinical applications. (KNS)